Last Price$261.5(3.3%)
Market Cap$31.5B
P/EBITDA LTM
8.1x
5Y avg
11.2x
Medical - Healthcare Plans industry
median
6.0x
Stock quality & Intrinsic value
6/10
2.1% undervalued
Humana Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 15.8x | 11.7x | 9.0x | 4.6x | 4.1x | 3.9x | 5.8x | 4.6x | 6.9x | 9.5x | 9.0x | 11.1x | 9.4x | 13.3x | 12.0x | 8.4x | 15.2x | 14.0x | 10.9x | 8.1x |
Overvalued or undervalued?
Check the intrinsic value for HUM
and see if it's the right time to invest.
Humana Inc. (HUM) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Humana Inc.HUM
9.2x
10.7%
(50.1%)
1.0%
Median Peer Set
6.0x
8.4%
(4.8%)
2.0%
Oscar Health, Inc.OSCR
41.7x
56.5%
N/A
0.3%
UnitedHealth Group IncorporatedUNH
18.3x
8.9%
(35.7%)
3.6%
Molina Healthcare, Inc.MOH
9.2x
19.3%
9.2%
2.9%
Cigna CorporationCI
7.7x
8.4%
(18.9%)
2.6%
CVS Health CorporationCVS
6.0x
4.2%
(43.6%)
1.2%
Centene CorporationCNC
5.3x
5.9%
27.4%
2.0%
Elevance Health Inc.ELV
2.1x
3.2%
(0.0%)
3.4%
Alignment Healthcare, Inc.ALHC
(40.1x)
27.2%
(4.8%)
(8.1%)
Clover Health Investments, Corp.CLOV
(42.6x)
(41.5%)
(31.3%)
(10.5%)
HUM key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 14,418.1 10.0% | 21,416.5 48.5% | 25,290.0 18.1% | 28,946.4 14.5% | 30,960.4 7.0% | 33,868.2 9.4% | 36,832.0 8.8% | 39,126.0 6.2% | 41,313.0 5.6% | 48,500.0 17.4% | 54,289.0 11.9% | 54,379.0 0.2% | 53,767.0 (1.1%) | 56,912.0 5.8% | 64,888.0 14.0% | 77,155.0 18.9% | 83,064.0 7.7% | 92,870.0 11.8% | 106,374.0 14.5% | 117,761.0 10.7% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5,395.0 | 5,830.0 | 6,355.0 | 7,639.0 | 7,318.0 | 7,277.0 | 6,567.0 | 7,525.0 | 7,381.0 | 10,052.0 | 10,121.0 | 12,671.0 | 13,188.0 | 0.0 |
% margin | 14,418.1 100.0% | 21,416.5 100.0% | 25,290.0 100.0% | 28,946.4 100.0% | 30,960.4 100.0% | 33,868.2 100.0% | 31,437.0 85.4% | 33,296.0 85.1% | 34,958.0 84.6% | 40,861.0 84.2% | 46,971.0 86.5% | 47,102.0 86.6% | 47,200.0 87.8% | 49,387.0 86.8% | 57,507.0 88.6% | 67,103.0 87.0% | 72,943.0 87.8% | 80,199.0 86.4% | 93,186.0 87.6% | 117,761.0 100.0% |
| Operating Expenses | 13,976.0 | 20,591.0 | 23,932.0 | 27,873.0 | 29,035.0 | 31,742.0 | 34,488.0 | 37,110.0 | 39,252.0 | 46,138.0 | 51,672.0 | 52,638.0 | 49,505.0 | 54,620.0 | 61,176.0 | 72,198.0 | 79,319.0 | 89,070.0 | 102,361.0 | 115,199.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 2,176.8 | 3,021.5 | 3,476.5 | 3,944.7 | 4,227.5 | 4,662.8 | 5,395.0 | 5,830.0 | 6,355.0 | 7,639.0 | 7,295.0 | 7,173.0 | 6,419.0 | 7,525.0 | 7,381.0 | 10,052.0 | 10,121.0 | 12,198.0 | 0.0 | 0.0 |
% margin | 421.7 2.9% | 762.1 3.6% | 1,289.3 5.1% | 992.8 3.4% | 1,601.8 5.2% | 1,749.6 5.2% | 2,235.0 6.1% | 2,016.0 5.2% | 2,061.0 5.0% | 2,362.0 4.9% | 2,617.0 4.8% | 1,741.0 3.2% | 4,262.0 7.9% | 2,292.0 4.0% | 3,712.0 5.7% | 4,957.0 6.4% | 3,745.0 4.5% | 3,800.0 4.1% | 4,013.0 3.8% | 2,562.0 2.2% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 105.0 | 140.0 | 192.0 | 186.0 | 189.0 | 242.0 | 218.0 | 242.0 | 283.0 | 326.0 | 401.0 | 0.0 | 0.0 |
| Interest Expense | 39.3 | 63.1 | 68.9 | 80.3 | 105.8 | 105.1 | 109.0 | 105.0 | 140.0 | 192.0 | 186.0 | 189.0 | 242.0 | 218.0 | 242.0 | 283.0 | 326.0 | 401.0 | 493.0 | 660.0 |
| Pre-tax Income | 421.7 | 762.1 | 1,289.3 | 992.8 | 1,601.8 | 1,749.6 | 2,235.0 | 1,911.0 | 1,921.0 | 2,170.0 | 2,431.0 | 1,552.0 | 4,020.0 | 2,063.0 | 3,456.0 | 4,600.0 | 3,354.0 | 3,568.0 | 3,383.0 | 1,721.0 |
% effective tax rate | 113.2 26.9% | 274.7 36.0% | 455.6 35.3% | 345.7 34.8% | 562.1 35.1% | 650.2 37.2% | 816.0 36.5% | 689.0 36.1% | 690.0 35.9% | 1,023.0 47.1% | 1,155.0 47.5% | 938.0 60.4% | 1,572.0 39.1% | 391.0 19.0% | 763.0 22.1% | 1,307.0 28.4% | 485.0 14.5% | 762.0 21.4% | 836.0 24.7% | 413.0 24.0% |
% margin | 308.5 2.1% | 487.4 2.3% | 833.7 3.3% | 647.2 2.2% | 1,039.7 3.4% | 1,099.4 3.2% | 1,419.0 3.9% | 1,222.0 3.1% | 1,231.0 3.0% | 1,147.0 2.4% | 1,276.0 2.4% | 614.0 1.1% | 2,448.0 4.6% | 1,683.0 3.0% | 2,707.0 4.2% | 3,367.0 4.4% | 2,933.0 3.5% | 2,806.0 3.0% | 2,489.0 2.3% | 1,207.0 1.0% |
| EPS | 1.91 | 2.97 | 5.00 | 3.87 | 6.21 | 6.55 | 8.58 | 7.56 | 7.81 | 7.44 | 8.54 | 4.11 | 16.94 | 12.24 | 20.20 | 25.47 | 22.79 | 22.20 | 20.09 | 10.02 |
| Diluted EPS | 1.87 | 2.90 | 4.91 | 3.83 | 6.15 | 6.47 | 8.46 | 7.47 | 7.73 | 7.36 | 8.44 | 4.07 | 16.81 | 12.16 | 20.10 | 25.31 | 22.67 | 22.08 | 20.00 | 9.99 |
% margin | 550.6 3.8% | 910.7 4.3% | 1,474.1 5.8% | 1,293.5 4.5% | 1,852.0 6.0% | 2,117.5 6.3% | 2,538.0 6.9% | 2,354.0 6.0% | 2,487.0 6.0% | 2,811.0 5.8% | 3,064.0 5.6% | 2,206.0 4.1% | 4,747.0 8.8% | 2,848.0 5.0% | 4,170.0 6.4% | 5,446.0 7.1% | 4,340.0 5.2% | 4,678.0 5.0% | 4,930.0 4.6% | 3,119.0 2.6% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Humana Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 8.1x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Humana Inc. have been 11.5x over the past three years, and 11.8x over the past five years.
2) Is Humana Inc.'s P/EBITDA LTM Good?
As of today, Humana Inc.'s P/EBITDA LTM is 8.1x, which is higher than industry median of 6.0x. It indicates that Humana Inc.'s P/EBITDA LTM is Bad.